Back to search
FDAFDA · Food and drugs·Recall number D-0767-2026

Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591; Marketed by: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591), NDC 61755-008-01

Published August 26, 2026 · Recall initiated: July 28, 2026

Summary

FDA records drug Class II recall D-0767-2026, published August 26, 2026 and initiated July 28, 2026. Recalling firm: Regeneron Pharmaceuticals Inc; Status: Ongoing; Reported quantity: 21,353 vials; Lot: Lot: 8494000002, Exp 7/31/28. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email if LIBTAYO has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
LIBTAYO
Manufacturer
Regeneron Pharmaceuticals Inc
Distributor
USA Nationwide
Lot
Lot: 8494000002, Exp 7/31/28
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591; Marketed by: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591), NDC 61755-008-01 recalled?

Yes. FDA published recall D-0767-2026 on August 26, 2026. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: LIBTAYO.